Advertisement
Canada markets close in 38 minutes

  • S&P/TSX

    21,779.48
    +71.04 (+0.33%)
     

  • S&P 500

    4,964.16
    -46.96 (-0.94%)
     

  • DOW

    37,929.21
    +153.83 (+0.41%)
     

  • CAD/USD

    0.7273
    +0.0010 (+0.13%)
     

  • CRUDE OIL

    83.38
    +0.65 (+0.79%)
     

  • Bitcoin CAD

    88,462.23
    +1,489.94 (+1.71%)
     

  • CMC Crypto 200

    1,381.20
    +68.58 (+5.42%)
     

  • GOLD FUTURES

    2,409.90
    +11.90 (+0.50%)
     

  • RUSSELL 2000

    1,935.75
    -7.21 (-0.37%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,276.07
    -325.43 (-2.09%)
     

  • VOLATILITY

    19.08
    +1.08 (+6.00%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

Today’s Research Reports on Stocks to Watch: Sage Therapeutics and Nektar Therapeutics

ACCESSWIRE

NEW YORK, NY / ACCESSWIRE / December 8, 2017 / Sage Therapeutics headed higher on Thursday and hit a brand new high after announcing that its depressive disorder MDD treatment SAGE-217 had seen positive mid-stage trial results. The stock also got price target increases from analysts. Shares of Nektar Therapeutics also soared higher despite any significant news.

RDI Initiates Coverage on:

Nektar Therapeutics
http://www.rdinvesting.com/report/?ticker=NKTR

Sage Therapeutics, Inc.
http://www.rdinvesting.com/report/?ticker=SAGE

Sage Therapeutics, Inc. shares blasted off on Thursday, closing the day up 70.04% on staggering trading volume compared to usual. The stock traded nearly 8.5 million shares yesterday compared to an average of just about 850,000. Shares also hit a brand new high of $169.58 during intra-day trading after the clinical-stage biotech company announced that its moderate to severe major depressive disorder MDD treatment SAGE-217 had seen positive mid-stage trial results. The company said the treatment had produced a highly significant mean reduction in the Hamilton Rating Scale for Depression among patients taking the drug, compared with patients who had received a placebo. According to Leerink analysts, "With the caveat of cross-trial comparisons, this difference is both larger — and attained faster — than what's observed for other antidepressants today." The firm has upped its price target on the stock from $123 to $246. RBC analysts also raised their price target to $280.

ADVERTISEMENT

Access RDI's Nektar Therapeutics Research Report at:
http://www.rdinvesting.com/report/?ticker=NKTR

Nektar Therapeutics shares closed up 10.34% on nearly 2.9 million shares traded on Thursday. There was no remarkable news from the company yesterday but last month shares had also soared over 100% according to S&P Global Market Intelligence. Last month the company reported its third-quarter results that revealed revenue growing to $152.9 million from $36.3 million. This increase is revenue was due to receiving the $128 million from Eli Lily. Eli Lilly had agreed to pay $150 million upfront payment on their partnership on NKTR-358, a pre-clinical-stage autoimmune-disease therapy. It was in September that the company announced positive data from its Phase 3 efficacy trial SUMMIT-07 that evaluated an investigational first-in-class opioid analgesic called NKTR-181 in reducing pain in opioid-naïve patients suffering from chronic lower back pain. The drug met all primary and secondary endpoints in the trial and has already received fast-track designation from the FDA.

Access RDI's Sage Therapeutics, Inc. Research Report at:
http://www.rdinvesting.com/report/?ticker=SAGE

Our Actionable Research on Nektar Therapeutics (NASDAQ: NKTR) and Sage Therapeutics, Inc. (NASDAQ: SAGE) can be downloaded free of charge at Research Driven Investing.

Research Driven Investing

We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.

RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.

Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.

CONTACT

For any questions, inquiries, or comments reach out to us directly at:

Address:

Research Driven Investing, Unit #901 511 Avenue of the Americas, New York, NY, 10011

Email:

contact@rdinvesting.com

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: RDInvesting.com